Systemic adverse effects after botulinum toxin type B (Myobloc) injections for the treatment of palmar hyperhidrosis [4]

Archives of Dermatology

Volumn 139, Issue 2, 2003, Pages 226-227

  Baumann, Leslie S ^a   Halem, Monica L ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; SODIUM CHLORIDE;

ADULT; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DYSPHAGIA; FOLLOW UP; HAND PALM; HUMAN; HYPERHIDROSIS; INDIGESTION; INTERVIEW; LETTER; MUSCLE WEAKNESS; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SEROTYPE; TREATMENT OUTCOME; UNITED STATES; VISUAL IMPAIRMENT; XEROSTOMIA;

ADULT; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; DEGLUTITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HAND; HUMANS; HYPERHIDROSIS; INJECTIONS, SUBCUTANEOUS; MALE; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; REMISSION, SPONTANEOUS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VISION DISORDERS;

EID: 0037319960     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.2.226     Document Type: Letter

References (6)

1. Stolman LP. Treatment of hyperhidrosis. Dermatol Clin. 1998;16:863-867.
2. Heckmann M, Ceballos-Baumann AO, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med. 2001;344:488-493.
3. Schwetz BA. First drug for cervical dystonia. JAMA. 2001;285:724.
4. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53: 1431-1438.
5. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999; 53:1439-1446.
6. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49:701-707.